For 12 years, brand-name REVATIO has helped treat pulmonary arterial hypertension (PAH) in adults. If you have PAH, ask your doctor about moving forward with brand-name REVATIO–only from Pfizer.
REVATIO is clinically proven
In a clinical study of 267 PAH patients,† REVATIO taken with epoprostenol:
Increased the distance people walked in a 6-minute defined time
Decreased pressure in the pulmonary artery‡
Helped lessen symptoms of PAH§
Helped slow down worsening changes in physical condition||
†All patients continued intravenous epoprostenol therapy.
‡Patients on REVATIO achieved a statistically important reduction in mPAP vs placebo.
§Measured by improvements in WHO functional class (classifies patients based on limitations of physical activity and symptoms).
||REVATIO patients had a significant delay to clinical worsening and were less likely to experience clinical worsening (death, lung transplantation, initiation of bosentan, or clinical deterioration) vs placebo.
Revatio is the brand you recognize
The REVATIO pill has a distinctive shape and marking to let you know you're getting the brand-name medication—pill to pill, month to month
Brand-name REVATIO is from a company you know—only from Pfizer
You have the assurance that Pfizer stands behind its manufacturing standards
Revatio Offers Savings To Patients
If eligible, patients may pay as little as $0 each month for brand-name REVATIO—and could save up to $12,000 a year.*